Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Heterogeneity of circulating CD57+ cytotoxic cell subsets across disease stage and aggressiveness in cutaneous T cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

SNSara NiyaziUniversity of South FloridaJPJavier Pinilla‐IbarzMoffitt Cancer Center

Discussion

Loading...

Member takes

Overview

Analysis reveals differences in cd57+ T cell levels across disease stages in cutaneous T cell lymphoma, suggesting potential links to aggressiveness.

Key Points

  • To assess the variation in circulating CD57+ cytotoxic cell subsets in patients with cutaneous T cell lymphoma and its relationship to clinical aggressiveness.
  • Analyzed peripheral blood CD57+ T- and NK cell subsets from 48 patients with mycosis fungoides and Sézary syndrome.
  • Used multicolor flow cytometry to measure different CD57+ T cell subsets.
  • Stratified Sézary syndrome patients by clinical aggressiveness and treatment status.
  • Conducted Kruskal-Wallis and Mann-Whitney U tests for statistical analysis.
  • Significant differences were observed in median levels of CD57+CD4+ T cells across disease stages (p=0.0069).
  • Higher CD57+CD4+ T cell levels noted in aggressive Sézary syndrome at diagnosis (81.24 cells/μL).
  • CD57+ NK cells showed significant variability across clinical subgroups (p=0.015).
  • CD57+CD8+ T cells and CD57+γδ+ T cells did not differ significantly across subgroups.

Cite This Study

Niyazi et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1e8https://doi.org/10.1182/blood-2025-3644
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Expanded CD4+CD57+ T-large granular lymphocytes: A diagnostic pitfall in blood staging of mycosis fungoides/Sézary syndrome2025
  2. 2Utility of combined <scp>CD39</scp> / <scp>CD73</scp> / <scp>CD38</scp> expression for the detection of malignant T cells in Sézary syndrome2026
  3. 3Dissecting Immune Determinants in Lesional Skin of Cutaneous T-Cell Lymphoma During Mogamulizumab Therapy2026
  4. 4Evaluation of Sézary cell marker expression and cell death behaviour upon in vitro treatment by flow cytometry in Sézary syndrome patients2024 · 1 citations
  5. 5Clinical and Prognostic Features of Erythrodermic Cutaneous T-Cell Lymphoma: A Retrospective Study of 35 Patients2025